UBS Group Raises LifeStance Health Group (NASDAQ:LFST) Price Target to $12.00

LifeStance Health Group (NASDAQ:LFST) had its price target boosted by stock analysts at UBS Group from $10.00 to $12.00 in a report released on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group’s price objective indicates a potential upside of 65.75% from the company’s previous close.

Several other research analysts have also weighed in on LFST. BTIG Research lifted their price objective on shares of LifeStance Health Group from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, February 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday, December 29th. Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Barclays assumed coverage on shares of LifeStance Health Group in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 price objective for the company. Finally, BMO Capital Markets initiated coverage on LifeStance Health Group in a report on Thursday, November 13th. They set an “outperform” rating and a $8.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, LifeStance Health Group has a consensus rating of “Moderate Buy” and a consensus target price of $9.67.

LifeStance Health Group Stock Performance

Shares of LifeStance Health Group stock opened at $7.24 on Thursday. The firm has a fifty day moving average of $7.13 and a two-hundred day moving average of $6.20. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.58 and a current ratio of 1.58. The stock has a market capitalization of $2.82 billion, a price-to-earnings ratio of 362.18 and a beta of 1.12. LifeStance Health Group has a 52 week low of $3.74 and a 52 week high of $8.30.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.02). LifeStance Health Group had a return on equity of 0.66% and a net margin of 0.68%.The company had revenue of $382.20 million for the quarter, compared to analyst estimates of $378.51 million. During the same period last year, the firm earned ($0.01) earnings per share. The firm’s revenue for the quarter was up 17.4% on a year-over-year basis. As a group, equities research analysts predict that LifeStance Health Group will post -0.18 EPS for the current year.

LifeStance Health Group announced that its board has approved a stock repurchase plan on Wednesday, February 25th that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 3.6% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In related news, Director Robert Bessler sold 119,942 shares of LifeStance Health Group stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $7.04, for a total value of $844,391.68. Following the sale, the director owned 1,318,983 shares of the company’s stock, valued at approximately $9,285,640.32. This trade represents a 8.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ann Varanakis sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total value of $345,000.00. Following the completion of the sale, the insider owned 315,610 shares in the company, valued at $2,177,709. The trade was a 13.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 270,086 shares of company stock valued at $1,891,264. Company insiders own 3.20% of the company’s stock.

Institutional Trading of LifeStance Health Group

A number of hedge funds and other institutional investors have recently made changes to their positions in LFST. Vanguard Group Inc. lifted its position in shares of LifeStance Health Group by 21.1% in the fourth quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock worth $124,608,000 after purchasing an additional 3,086,506 shares in the last quarter. Silversmith Partners I GP LLC bought a new stake in LifeStance Health Group during the 4th quarter worth about $100,842,000. Dimensional Fund Advisors LP boosted its stake in shares of LifeStance Health Group by 6.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 8,906,465 shares of the company’s stock worth $62,704,000 after buying an additional 542,858 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of LifeStance Health Group by 27.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,118,027 shares of the company’s stock valued at $43,071,000 after acquiring an additional 1,324,691 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of LifeStance Health Group by 62.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock valued at $26,363,000 after acquiring an additional 1,839,465 shares during the last quarter. 85.50% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Board authorizes a $100 million share repurchase (up to ~3.6% of shares), signaling management thinks the stock is undervalued and reducing float. LifeStance to Repurchase $100M
• Positive Sentiment: Multiple firms raised price targets and ratings (UBS to $12, Canaccord to $10, KeyCorp to $9), increasing visible upside and buy-side interest. Analyst Price Target Raises
• Positive Sentiment: Company set 2026 revenue target of $1.615B–$1.655B and highlighted progress on AI and EHR initiatives that can drive scale and margin expansion over time. 2026 Revenue Target & Initiatives
• Neutral Sentiment: Coverage roundup: several analysts reviewed the stock following the quarter; the market reaction depends on whether upgrades translate into sustained buy-side flows. 6 Analysts Assess LFST
• Negative Sentiment: Q4 EPS missed expectations (reported ~$0.03 vs. ~$0.06 expected) despite revenue beating estimates; EPS weakness and still-modest margins remain near-term headwinds. Q4 2025 Earnings Highlights
• Negative Sentiment: Selling stockholders filed a secondary offering of 25M shares (company not raising proceeds), creating potential supply/overhang that can cap near-term upside. Secondary Public Offering

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.